Trial Profile
A Phase I, Open-Label, Multiple Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of RRx-001 in Subjects With Advanced Solid Tumors or Lymphomas For Which There Are No Currently Accepted Curative Therapies.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 21 Aug 2015
Price :
$35
*
At a glance
- Drugs Nibrozetone (Primary)
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions
- Acronyms DINAMIC
- Sponsors EpicentRx
- 19 Aug 2015 Results published in Lancet Oncology, as per EpicentRx media release.
- 18 Aug 2015 Results published in the Lancet Oncology.
- 19 May 2015 Status changed from recruiting to completed as per ClinicalTrials.gov record.